Endpoints in Heart Failure Drug Development
Heart failure (HF) is a major health problem worldwide. The development of effective drug and/or device therapy is crucial to mitigate the significant morbidity, mortality and healthcare costs associated with HF. The choice of endpoint in clinical trials has important practical and clinical implicat...
Main Authors: | Aliza Hussain, Arunima Misra, Biykem Bozkurt |
---|---|
Format: | Article |
Language: | English |
Published: |
Radcliffe Medical Media
2022-01-01
|
Series: | Cardiac Failure Review |
Online Access: | https://www.cfrjournal.com/articleindex/cfr.2021.13 |
Similar Items
-
Biomarkers for Heart Failure Prediction and Prevention
by: Prasanti Alekhya Kotta, et al.
Published: (2023-12-01) -
QUALITY OF LIFE – AN IMPORTANT ENDPOINT OF TREATMENT IN PATIENTS WITH HEART FAILURE
by: Camelia C. DIACONU
Published: (2022-09-01) -
New challenges in endpoints for drug development in advanced melanoma.
by: Ribas, A, et al.
Published: (2012) -
The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials
by: Luxi Ji, et al.
Published: (2023-03-01) -
Selection of Endpoints for Clinical Studies of Ophthalmic Drugs
by: M. O. Komarova
Published: (2021-10-01)